Everything you need to win Cue Biopharma — in one platform.
Who to reach, what to say, and why now on Cue Biopharma — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Cue Biopharma — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Boehringer Ingelheim and Cue Biopharma Partner for Developing Autoimmune Therapy
Apr 14, 2025•about 1 year ago
Contract Type
partnership
BostonBiotechnologyHealth CareTherapeutics
Description
Boehringer Ingelheim and Cue Biopharma have announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. The partnership aims to bolster Boehringer’s autoimmune and inflammatory disease pipeline portfolio, focusing on areas of high unmet patient need
Company Information
Company
Cue Biopharma
Location
Boston, Massachusetts, United States
About
Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease. Cue Biopharma’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune system through the selective modulation of disease-relevant T cells without the adverse effects of broad systemic immune activation.
BostonBiotechnologyHealth CareTherapeutics